|
|
Article: Cancer Drug Target Chk1 May Also Be Source of Drug Resistance; New Findings Suggest Balancing Chk1 Activity Will Produce Less Toxic Cancer Drugs.
- Article from:
- AScribe Medicine News Service
- Article date:
- September 1, 2005
CopyrightCOPYRIGHT 2005 AScribe. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: The Burnham Institute
LA JOLLA, Calif., Sept. 1 (AScribe Newswire) -- A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects.
Robert Abraham, Ph.D., former ...